Patents by Inventor Eliezer A. Rachmilewitz

Eliezer A. Rachmilewitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serum-derived factor inducing cell differentiation and medical uses thereof
    Patent number: 6783775
    Abstract: The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: August 31, 2004
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tony Peled, Eitan Fibach, Eliezer A. Rachmilewitz
  • Serum-derived factor inducing cell differentiation and medical uses thereof
    Publication number: 20020054916
    Abstract: The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells.
    Type: Application
    Filed: November 9, 2001
    Publication date: May 9, 2002
    Inventors: Tony Peled, Eitan Fibach, Eliezer A. Rachmilewitz
  • Serum-derived factor inducing cell differentiation and medical uses thereof
    Patent number: 6372262
    Abstract: The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: April 16, 2002
    Assignee: Hadasit Medical Research Services & Development Company Ltd.
    Inventors: Tony Peled, Eitan Fibach, Eliezer A. Rachmilewitz